RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives
D Alawieh, L Cysique-Foinlan, C Willekens… - Blood Cancer …, 2024 - nature.com
NRAS and KRAS activating point mutations are present in 10–30% of myeloid malignancies
and are often associated with a proliferative phenotype. RAS mutations harbor allele …
and are often associated with a proliferative phenotype. RAS mutations harbor allele …
[HTML][HTML] Therapeutic biomarkers in acute myeloid leukemia: functional and genomic approaches
K Bhatia, V Sandhu, MH Wong, P Iyer… - Frontiers in …, 2024 - ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is clinically and genetically a heterogeneous disease
characterized by clonal expansion of abnormal hematopoietic progenitors. Genomic …
characterized by clonal expansion of abnormal hematopoietic progenitors. Genomic …
Targeting CCL2/CCR2 signaling overcomes MEK inhibitor resistance in Acute Myeloid Leukemia
RV Modak, KG de Oliveira Rebola, J McClatchy… - Clinical Cancer …, 2024 - AACR
Purpose: Emerging evidence underscores the critical role of extrinsic factors within the
microenvironment in protecting leukemia cells from therapeutic interventions, driving …
microenvironment in protecting leukemia cells from therapeutic interventions, driving …
Combating Acute Myeloid Leukemia via Sphingosine Kinase 1 Inhibitor-Nanomedicine Combination Therapy with Cytarabine or Venetoclax
TM Nguyen, P Joyce, DM Ross, K Bremmell… - Pharmaceutics, 2024 - mdpi.com
MP-A08 is a novel sphingosine kinase 1 (SPHK1) inhibitor with activity against acute
myeloid leukemia (AML). A rationally designed liposome-based encapsulation and delivery …
myeloid leukemia (AML). A rationally designed liposome-based encapsulation and delivery …
C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription
M Du, M Wang, M Liu, S Fu, Y Lin, Y Huo, J Yu… - Journal of Experimental …, 2024 - Springer
Background Acute myeloid leukemia (AML) with biallelic (CEBPA bi) as well as single
mutations located in the bZIP region is associated with a favorable prognosis, but the …
mutations located in the bZIP region is associated with a favorable prognosis, but the …
High throughput screening aids clinical decision‐making in refractory acute myeloid leukaemia
SJ Jessop, N Fuentos‐Bolanos, C Mayoh… - Cancer …, 2024 - Wiley Online Library
Background Despite advances in therapeutics for adverse‐risk acute myeloid leukaemia
(AML), overall survival remains poor, especially in refractory disease. Comprehensive …
(AML), overall survival remains poor, especially in refractory disease. Comprehensive …
Oxadiazole Derivatives of Diclofenac as an Anti-proliferative Agent for B-cell Non-Hodgkin Lymphoma: An In vitro and In Silico Studies
S Qayyum, A Jabeen, S Ashraf, F Seraj… - Medicinal …, 2024 - ingentaconnect.com
> Background: Non-Hodgkin lymphoma of B cell origin is the common type of lymphoma-
related malignancy with poor response rate with conventional front-line therapies. Aim: The …
related malignancy with poor response rate with conventional front-line therapies. Aim: The …
[HTML][HTML] Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial
MY Konopleva, M Dail, NG Daver, JS Garcia… - … Myeloma and Leukemia, 2024 - Elsevier
Background Therapies for relapsed/refractory acute myeloid leukemia remain limited and
outcomes poor, especially amongst patients who are ineligible for cytotoxic chemotherapy or …
outcomes poor, especially amongst patients who are ineligible for cytotoxic chemotherapy or …
Combination Therapies Targeting Extracellular Signal Regulated Kinases 1/2 and Histone Deacetylase 6 as Potential Therapeutics for B-Cell Lymphoma
M Asslan - 2024 - escholarship.mcgill.ca
B cell lymphomas are a heterogeneous group of malignancies affecting B lymphocytes that
play an essential role in immune responses as they differentiate into antibodysecreting …
play an essential role in immune responses as they differentiate into antibodysecreting …
[PDF][PDF] Identifizierung und Charakterisierung von Medikamenten zur synergistischen Kombination mit Inhibitoren des Menin-MLL-Chromatinkomplexes für die …
HL Stiller - openscience.ub.uni-mainz.de
Während hämatologische Neoplasien insgesamt zu den selteneren Krebserkrankungen
gehören, nimmt ihre Inzidenz mit höherem Lebensalter stark zu [5]. Die heterogene …
gehören, nimmt ihre Inzidenz mit höherem Lebensalter stark zu [5]. Die heterogene …